The aim of HIO is to develop anticancer immunotherapy
BASED ON A TECHNOLOGY PLATFORM
TUMOR DEFENCE BREAKER V-DOS47
Helix Immuno-Oncology: a strong management team
SPECIALISING IN BIOTECHNOLOGY
AND LIFE SCIENCE
The company's objective is to create access to the latest medical advances.
IN PARTICULAR IMMUNOTHERAPY FOR ONCOLOGICAL PATIENTS
HELIX
IMMUNO-ONCOLOGY
Capital Group Daughter of Helix Biopharma

Helix Immuno-Oncology (formerly: Helix Polska) is a subsidiary of the Canadian biopharmaceutical company Helix BioPharma, established in 2013. Helix Immuno-Oncology (formerly: Helix Polska) is based in Warsaw, and the company is headed by a strong management team specialising in biotechnology and life science. Polish scientists participate in the development of original technologies in cancer therapy and support research on oncological drugs conducted in Poland, Canada and the USA. 

 

Helix actively develops innovative products for cancer immunotherapy based on proprietary proprietary technologies. The company's drug development initiatives are based on technology platform: V-DOS47. This innovation is used in the treatment of malignant solid tumors.

Helix Immuno-Oncology is a biotechnology company with global competence. Helix Immuno-Oncology (formerly: Helix Polska) is based in Warsaw, while Helix BioPharma is headquartered in Toronto, Canada. Helix BioPharma is currently listed on the Toronto Stock Exchange. The Company actively cooperates with oncological clinics and research centres in Canada, the USA and Poland.

 

Helix BioPharma's research is conducted in cooperation with an international group of scientists - specialists of the highest competence in Poland and abroad.

HELIX
IMMUNO-ONCOLOGY
Capital Group Daughter of Helix Biopharma
Media about us
18.04
2018
7th Conference "CePT - a platform for the development of innovative biomedicine 2018"
   
12.04
2018
Oncology: the company will present the research results at the AACR